Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2010
03/09/2010CA2308904C Process for the inactivation of viruses
03/09/2010CA2306313C Dipeptide nitriles
03/09/2010CA2172153C Regulation of bcl-2 gene expression
03/09/2010CA2159702C High molecular and low molecular fractions of von willebrand factor
03/09/2010CA2156007C Purification of alpha-1 proteinase inhibitor using novel chromatographic separation conditions
03/09/2010CA2140598C Prolineamide derivatives
03/04/2010WO2010025438A2 Methods of treatment using single doses of oritavancin
03/04/2010WO2010025421A2 Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
03/04/2010WO2010025380A2 Analysis of hcv genotypes
03/04/2010WO2010025341A2 Determining age ranges of skin samples
03/04/2010WO2010025316A1 Composition and methods for relief of neuropathological pain
03/04/2010WO2010025247A1 Epicatechin glucosyltransferase
03/04/2010WO2010025126A1 Rapidly disintegrating tablets comprising lipase, amylase, and protease
03/04/2010WO2010025016A2 Enhancement of transgene expression from virus-based vaccine vectors using suppressors of the type 1 interferon response
03/04/2010WO2010024927A2 Treatment of amyloidoses using myelin basic protein and fragments thereof
03/04/2010WO2010024772A1 Aspartyl protease inhibitors
03/04/2010WO2010024676A1 Delivery of a cd40 agonist to a tumor draining lymph node of a subject
03/04/2010WO2010024557A2 Biopolymer conjugates comprising an interleukin-11 analog
03/04/2010WO2010024460A1 Adiponectin for treating pulmonary disease
03/04/2010WO2010024204A1 Wrinkle-diminishing agent
03/04/2010WO2010024118A1 Novel recombinant protein having caspase recruitment domain applied thereto, and use thereof
03/04/2010WO2010024108A1 Prophylactic or therapeutic agent for influenza virus infection
03/04/2010WO2010023917A1 Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof
03/04/2010WO2010023858A1 Therapeutic agent for heart failure
03/04/2010WO2010023850A1 Method for treating or preventing bladder cancer using the depdc1 polypeptide
03/04/2010WO2010023544A1 Compositions and methods for delivery of protein-coding rnas to correct mitochondrial dysfunction
03/04/2010WO2010023341A1 New chitinase of bacterial origin with broad fungicide spectrum
03/04/2010WO2010023218A1 Method and means for activating memory b lymphocytes
03/04/2010WO2010023207A2 Antimicrobial agents
03/04/2010WO2010022639A1 Target-specific double-mutant fusion protein
03/04/2010WO2010006117A3 Cyclosporin derivatives for treating ocular and dermal diseases and conditions
03/04/2010WO2010000686A3 Composition for topical use comprising quinine
03/04/2010WO2009158238A3 Fibroblast growth factor (fgf) analogs and uses thereof
03/04/2010WO2009152519A3 Novel antiviral peptides against influenza virus
03/04/2010WO2009151304A3 Composition comprised of akap12 and uses of akap12 mutant zebrafish as an animal model
03/04/2010WO2009149307A3 Compositions and methods for restoring mitochondrial electron transfer function
03/04/2010WO2009149306A9 Complement depleting compounds and methods of treating cancer comprising monoclonal antibody therapy and said complement depleting compounds
03/04/2010WO2009149094A3 Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
03/04/2010WO2009140676A3 Compositions and methods for inhibition of retroviruses
03/04/2010WO2009139984A3 Treatment of bladder dysfunction using liposomal botulinum toxin
03/04/2010WO2009139599A3 Cell-permeable p27 recombinant protein, a polynucleotide that codes the same and an anti-cancer composition containing the same as an active ingredient
03/04/2010WO2009138987A3 Molecules interfering with binding of calbindin to inositol monophosphatase for the treatment of mood disorders
03/04/2010WO2009137572A3 Inhibition of gliadin peptides
03/04/2010WO2009135029A3 Compositions and methods to treat urinary incontinence
03/04/2010WO2009125423A3 Compositions useful for the treatment of diabetes and other chronic disorder
03/04/2010WO2009120810A3 Neurodegenerative disorders
03/04/2010WO2009114520A9 Compositions for treatment with metallopeptidases, methods of making and using the same
03/04/2010WO2009110952A3 Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
03/04/2010WO2009109532A9 Use of defensins against tuberculosis
03/04/2010WO2009024964A3 Composition and method for the treatment of otitis externa
03/04/2010WO2009022328A3 Regulators of mmp-9 and uses therof
03/04/2010WO2009007992A8 Pharmaceutical composition produced by microprecipitation
03/04/2010WO2009003284A8 Novel peptides, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same
03/04/2010WO2008155658A3 Variegin from amblyomma variegatum is a direct thrombin inhibitor
03/04/2010WO2008103044A8 Non-natural recombinant gelatins with enhanced functionality
03/04/2010US20100058489 Nucleic Acid Encoding A Brain Derived Tau Kinase Polypeptide and Methods of Use Thereof
03/04/2010US20100058488 Protein formulations comprising s1-5
03/04/2010US20100057218 Methods of administering a material into a patient for dermal enhancement
03/04/2010US20100057047 Delivery device and method
03/04/2010US20100056551 Anti-cancer cyclopenta [G] quinazoline compounds
03/04/2010US20100056460 Combination of organic compounds
03/04/2010US20100056459 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
03/04/2010US20100056458 Peptides Inhibiting Angiotensin-Converting Enzyme
03/04/2010US20100056457 Zinc Finger Binding Domains for CNN
03/04/2010US20100056456 Omega Conotoxins
03/04/2010US20100056455 Therapies Which Act on Neuropeptide S Receptors
03/04/2010US20100056454 Method for Screening Modulators of Apoptosis
03/04/2010US20100056453 Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides
03/04/2010US20100056452 Angiogenesis-promoting substrate
03/04/2010US20100056451 Stabilized Pharmaceutical Peptide Compositions
03/04/2010US20100056450 Method For Reducing Postprandial Blood Glucose Levels With A Whey Protein/Fiber Composition
03/04/2010US20100056449 Whey Protein Pre-Load
03/04/2010US20100056448 Glut-1 as a receptor for htlv envelopes and its uses
03/04/2010US20100056447 Immunization against chlamydia pneumoniae
03/04/2010US20100056446 NA+K+-ATPase-Specific Peptide Inhibitors/Activators of SRC and SRC Family Kinases
03/04/2010US20100056445 Adiponectin for the treatment and diagnosis of albuminuria
03/04/2010US20100056444 Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors
03/04/2010US20100056443 Radiopharmaceutical to be used in distinction between inflammations and infections in orthopaedic implants
03/04/2010US20100056442 Use of gpr101 receptor in methods to identify modulators of hypothalamic proopiomelanocortin (pomc)-derived biologically active peptide secretion useful in the treatment of pomc-derived biologically
03/04/2010US20100056441 Method for Inhibiting Angiogenesis
03/04/2010US20100056440 Compositions and methods for administering gdnf ligand family proteins
03/04/2010US20100056439 Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
03/04/2010US20100056438 Methods of producing nano-and microcapsules of spider silk proteins
03/04/2010US20100056437 Compositions for Treating or Preventing Myocardial Damage or Heart Failure
03/04/2010US20100056436 Pharmaceutical Compositions Including Low Dosages of Desmopressin
03/04/2010US20100056435 Depsipeptides and Their Therapeutic Use
03/04/2010US20100056434 Depsipeptides and Their Therapeutic Use
03/04/2010US20100056433 Novel Peptides for Use in the Treatment of Obesity
03/04/2010US20100056432 Template-fixed peptidomimetics with antibacterial activity
03/04/2010US20100056431 Medical uses
03/04/2010US20100056430 Treatment and Method for Eliminating or Reducing Foot Odor
03/04/2010US20100056429 Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
03/04/2010US20100056428 Modified proteins
03/04/2010US20100056427 N-terminal derivatisation of proteins with polysaccharides
03/04/2010US20100056426 Use of iron chelator for the treatment of myocardial infarction
03/04/2010US20100056425 Absorption enhancers such as E.G. BHT, BHA or propyl gallate
03/04/2010US20100056424 Cosmetic use of chitinase-type proteins
03/04/2010US20100056423 Bacterial-Derived BLIS for Treatment of Acne
03/04/2010US20100055786 Method for treating kidney disorders
03/04/2010US20100055763 Method for the production and purification of retroviral vectors
1 ... 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 ... 3163